JP2008521829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521829A5 JP2008521829A5 JP2007543602A JP2007543602A JP2008521829A5 JP 2008521829 A5 JP2008521829 A5 JP 2008521829A5 JP 2007543602 A JP2007543602 A JP 2007543602A JP 2007543602 A JP2007543602 A JP 2007543602A JP 2008521829 A5 JP2008521829 A5 JP 2008521829A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- optionally
- heterocycloalkyl
- group
- substituted lower
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003342 alkenyl group Chemical group 0.000 claims 34
- 125000000304 alkynyl group Chemical group 0.000 claims 34
- 229910052799 carbon Inorganic materials 0.000 claims 32
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 29
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 22
- 229910052757 nitrogen Inorganic materials 0.000 claims 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 21
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 20
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 20
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 19
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 19
- 125000003107 substituted aryl group Chemical group 0.000 claims 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims 16
- 150000001336 alkenes Chemical class 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000001345 alkine derivatives Chemical class 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000004414 alkyl thio group Chemical group 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000003573 thiols Chemical class 0.000 claims 4
- -1 alkylthio sulfur Chemical compound 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010007749 Cataract diabetic Diseases 0.000 claims 1
- 108700012841 Cholesteryl Ester Transfer Protein Deficiency Proteins 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000007025 diabetic cataract Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 208000015076 hyperalphalipoproteinemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63174604P | 2004-11-30 | 2004-11-30 | |
| US71531205P | 2005-09-07 | 2005-09-07 | |
| PCT/US2005/043271 WO2006060456A2 (en) | 2004-11-30 | 2005-11-29 | Indole derivatives for use as ppar ppar active compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008521829A JP2008521829A (ja) | 2008-06-26 |
| JP2008521829A5 true JP2008521829A5 (enExample) | 2009-01-29 |
Family
ID=36565676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543602A Pending JP2008521829A (ja) | 2004-11-30 | 2005-11-29 | Ｐｐａｒ活性化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7531568B2 (enExample) |
| EP (1) | EP1819673A2 (enExample) |
| JP (1) | JP2008521829A (enExample) |
| AU (1) | AU2005311925A1 (enExample) |
| CA (1) | CA2588953A1 (enExample) |
| WO (1) | WO2006060456A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2008094860A2 (en) | 2007-01-30 | 2008-08-07 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists |
| CN103497185A (zh) | 2007-03-14 | 2014-01-08 | 兰贝克赛实验室有限公司 | 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物 |
| EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP4008327A1 (en) | 2009-04-29 | 2022-06-08 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| KR20120097512A (ko) | 2009-11-18 | 2012-09-04 | 플렉시콘, 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| KR20120112623A (ko) | 2009-12-23 | 2012-10-11 | 플렉시콘, 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| CN103201262B (zh) | 2010-08-20 | 2016-06-01 | 艾米拉医药股份有限公司 | 自分泌运动因子抑制剂及其用途 |
| WO2012109075A1 (en) | 2011-02-07 | 2012-08-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| RU2631487C2 (ru) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Модуляция киназ и показания к её применению |
| EP2714680B1 (en) | 2011-05-27 | 2015-11-25 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
| PE20151280A1 (es) | 2012-12-21 | 2015-09-12 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| NZ630875A (en) | 2013-03-15 | 2017-12-22 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| CA2912568A1 (en) | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2016044067A1 (en) | 2014-09-15 | 2016-03-24 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CA3129180A1 (en) | 2015-09-21 | 2017-03-30 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| US9938273B2 (en) | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6921846B6 (ja) | 2016-03-16 | 2021-09-15 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼ調節およびその適応症のための化合物および方法 |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| JP7193460B2 (ja) | 2016-12-23 | 2022-12-20 | プレキシコン インコーポレーテッド | Ｃｄｋ８調節およびその適応症のための化合物および方法 |
| WO2018175311A1 (en) | 2017-03-20 | 2018-09-27 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
| US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| KR102615829B1 (ko) | 2017-07-25 | 2023-12-20 | 플렉시콘 인코퍼레이티드 | 키나제를 조정하는 화합물의 제제 |
| AU2018348241B2 (en) | 2017-10-13 | 2023-01-12 | Opna Bio SA | Solid forms of a compound for modulating kinases |
| CA3080197C (en) | 2017-10-27 | 2023-12-19 | Plexxikon Inc. | Formulations of a compound modulating kinases |
| EP3768666A1 (en) | 2018-03-20 | 2021-01-27 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
| CA3176237A1 (en) | 2020-04-29 | 2021-11-04 | Jack Lin | Synthesis of heterocyclic compounds |
| CN115894330B (zh) * | 2022-09-06 | 2024-12-10 | 吉林医药学院 | 一种1-乙酰基-1h-吲哚-3-基乙酸酯衍生物的合成方法和应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1482844A (fr) * | 1964-12-31 | 1967-06-02 | Merck & Co Inc | Procédé de préparation de nouveaux acides 2-[2-(phénylalkyl substitué)-3-indolyl] aliphatiques inférieurs |
| US3489767A (en) * | 1966-01-12 | 1970-01-13 | Sumitomo Chemical Co | 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives |
| US3511841A (en) * | 1967-05-29 | 1970-05-12 | Sterling Drug Inc | 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines |
| US3557142A (en) * | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
| FR2009259A1 (enExample) | 1968-05-24 | 1970-01-30 | Acraf | |
| GB1573212A (en) * | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
| DE3246932A1 (de) * | 1982-12-16 | 1984-06-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | Substituierte 5h-pyrimido(5,4-b)indole |
| US4568649A (en) * | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
| US4626513A (en) * | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
| DE3483099D1 (de) | 1984-03-15 | 1990-10-04 | Immunex Corp | Test zur sofortigen feststellung von liganden, testsatz und seine herstellung. |
| US5688655A (en) * | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
| GB9004301D0 (en) | 1990-02-26 | 1990-04-18 | Fujisawa Pharmaceutical Co | Indolebutyric acid derivatives and process for preparation thereof |
| US5075313A (en) * | 1990-09-13 | 1991-12-24 | Eli Lilly And Company | 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof |
| EP0610793A1 (en) * | 1993-02-08 | 1994-08-17 | Takeda Chemical Industries, Ltd. | Tetracyclic morpholine derivatives and their use or analgesics |
| IL109309A (en) | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| DE69434998T2 (de) * | 1993-05-27 | 2008-03-13 | Aventis Pharmaceuticals Inc. | Topologisch getrennte, kodierende Festphasen-Bibliotheken |
| US5840485A (en) * | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
| US5763198A (en) * | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
| GB9416467D0 (en) | 1994-08-13 | 1994-10-05 | Wellcome Found | Compounds for use in medicine |
| US5747276A (en) * | 1995-09-15 | 1998-05-05 | The Scripps Research Institute | Screening methods for the identification of novel antibiotics |
| US6294330B1 (en) * | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
| WO1998039471A1 (en) * | 1997-03-07 | 1998-09-11 | Tropix, Inc. | Protease inhibtor assay |
| US6178384B1 (en) * | 1997-09-29 | 2001-01-23 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for selecting a molecule based on conformational free energy |
| ATE333275T1 (de) * | 1998-02-23 | 2006-08-15 | Univ South Alabama | Indole-3-propionsäure, ihre salze und ester als arzneimittel |
| US6329389B1 (en) * | 1998-04-08 | 2001-12-11 | Takeda Chemical Industries, Ltd. | Amine compounds, their production and use |
| DE19821002A1 (de) * | 1998-05-11 | 1999-11-18 | Dresden Arzneimittel | Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP1085846A2 (en) * | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| TNSN99224A1 (fr) * | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
| IL145923A0 (en) | 1999-04-28 | 2002-07-25 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
| PT1177187E (pt) * | 1999-04-28 | 2007-09-03 | Sanofi Aventis Deutschland | Derivados ácidos de di-arilo como ligados do receptor ppar. |
| ATE316071T1 (de) | 1999-09-17 | 2006-02-15 | Kyorin Seiyaku Kk | O-anisamid-derivate |
| FR2801585B1 (fr) | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
| SI1285908T1 (sl) | 2000-05-29 | 2008-12-31 | Kyorin Seiyaku Kk | Substituirani fenilpropionski kislinski derivati |
| MXPA03003021A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de eter y composiciones para el control del colesterol y usos relacionados. |
| KR101059776B1 (ko) * | 2001-06-12 | 2011-08-26 | 웰스테트 테라퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
| BR0212512A (pt) * | 2001-09-14 | 2004-10-26 | Tularik Inc | Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta |
| MXPA04007414A (es) | 2002-02-01 | 2004-10-11 | Hoffmann La Roche | Indoles sustituidos como agonistas alfa-1. |
| US6806265B2 (en) * | 2002-05-16 | 2004-10-19 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
| WO2004007439A1 (ja) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | ビアリール誘導体 |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| CA2511214C (en) | 2002-12-20 | 2012-12-18 | Tularik, Inc. | Asthma and allergic inflammation modulators |
| WO2004056740A1 (en) | 2002-12-20 | 2004-07-08 | Novo Nordisk A/S | Dicarboxylic acid derivatives as ppar-agonists |
| AU2003303681A1 (en) | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Fused heterocyclic derivates as ppar modulators |
| CA2532403A1 (en) * | 2003-07-17 | 2005-02-03 | James Arnold | Ppar active compounds |
| US7348338B2 (en) * | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| WO2005012221A1 (ja) | 2003-08-04 | 2005-02-10 | Ono Pharmaceutical Co., Ltd. | ジフェニルエーテル化合物、その製造方法および用途 |
| US20070232681A1 (en) | 2003-10-14 | 2007-10-04 | Oxagen Limited | Compounds Having Crth2 Antagonist Activity |
| WO2005040112A1 (en) | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| CA2541751A1 (en) | 2003-10-14 | 2005-04-28 | Eli Lilly And Company | Phenoxyether derivatives as ppar modulators |
| GB2407318A (en) | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
| GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
| WO2005054176A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| RU2240793C1 (ru) | 2003-12-02 | 2004-11-27 | Лимонов Виктор Львович | Противоопухолевое средство |
| WO2005056522A2 (en) | 2003-12-04 | 2005-06-23 | National Health Research Institutes | Indole compounds |
| WO2005060958A1 (en) | 2003-12-19 | 2005-07-07 | Kalypsys, Inc. | (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes |
| WO2005092131A1 (en) | 2004-03-01 | 2005-10-06 | Mirko Uzelac | Bipartite butcher's handshalter with couple |
| GB0412914D0 (en) | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
-
2005
- 2005-11-29 WO PCT/US2005/043271 patent/WO2006060456A2/en not_active Ceased
- 2005-11-29 CA CA002588953A patent/CA2588953A1/en not_active Abandoned
- 2005-11-29 EP EP05852496A patent/EP1819673A2/en not_active Withdrawn
- 2005-11-29 US US11/289,656 patent/US7531568B2/en not_active Expired - Fee Related
- 2005-11-29 AU AU2005311925A patent/AU2005311925A1/en not_active Abandoned
- 2005-11-29 JP JP2007543602A patent/JP2008521829A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008521829A5 (enExample) | ||
| JP2008521831A5 (enExample) | ||
| JP2009509932A5 (enExample) | ||
| JP2009507079A5 (enExample) | ||
| JP2010526145A5 (enExample) | ||
| JP2009507846A5 (enExample) | ||
| ES2752039T3 (es) | Agente terapéutico para la dislipidemia | |
| JP2010514829A5 (enExample) | ||
| JP2007500720A5 (enExample) | ||
| JP2012515724A5 (enExample) | ||
| JP2009531280A5 (enExample) | ||
| RU2009137124A (ru) | Соединения, активные в отношении ppar | |
| JP6595078B2 (ja) | アミノカルボニルカルバメート化合物 | |
| RU2008110697A (ru) | Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом) | |
| WO2011083999A3 (ko) | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 | |
| JPS62228054A (ja) | ５−リポキシゲナ−ゼ抑制剤としての新規フエノ−ル系チオエ−テル | |
| JP2012097105A5 (enExample) | ||
| TW201121544A (en) | Novel phenol derivative | |
| JP2009528275A5 (enExample) | ||
| JP2013523623A5 (enExample) | ||
| RU2017141446A (ru) | Энантиомеры 2-гидроксипроизводных жирных кислот | |
| CN104254514B (zh) | 4‑((取代苯基)二氟甲基)苯氧基羧酸衍生物及其制备方法和用途 | |
| EP3366686A3 (en) | Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof | |
| WO2010098286A1 (ja) | ミネラルコルチコイド受容体拮抗薬を含有する医薬 | |
| US8633335B2 (en) | Retinoid prodrug compound |